New smart drug targets Hard-to-Treat cancers

NCT ID NCT06303505

Recruiting now Disease control Sponsor: Tubulis GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cells that have a specific marker (NaPi2b). The trial has two parts: first, finding the safest dose, and then comparing doses to see which works best. Participants receive the drug intravenously every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TUB-040 (an antibody-drug conjugate that delivers a chemotherapy drug directly to cancer cells)

What this could lead to

If successful, this could provide a new treatment option for patients with hard-to-treat ovarian or lung cancer who have run out of standard therapies.

What could go wrong

This is an early-phase trial (Phase 1/2a) with a small number of patients, so the drug may not work or may cause significant side effects. The cancer types are aggressive and resistant to current treatments, making success uncertain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma non-small cell lung carcinoma ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL-CELL LUNG CANCER OVARIAN CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Arensia Exploratory Medicine
RECRUITING

Cluj-Napoca, Romania

Contact Email: •••••@•••••
Arensia Exploratory Medicine
RECRUITING

Kyiv, Ukraine

Contact Email: •••••@•••••
Charité Universitätsmedizin Berlin
RECRUITING

Berlin, 10117, Germany

Contact Email: •••••@•••••
Christ Hospital
RECRUITING

Cincinnati, Ohio, 45219, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Clínica universidad de Navarra
RECRUITING

Madrid, 28027, Spain

Contact Email: •••••@•••••
Guy's Hospital
RECRUITING

London, SE1 9RT, United Kingdom

Contact Email: •••••@•••••
Mount Sinai
RECRUITING

New York, New York, 10011, United States

Contact Email: •••••@•••••
NEXT Oncology Madrid
RECRUITING

Madrid, 28223, Spain

Contact Email: •••••@•••••
Next Oncology Dallas
RECRUITING

Irving, Texas, 75039, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Next Oncology Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

Contact Phone: •••-•••-••••
OU Health Stephenson Cancer Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States

Contact Email: •••••@•••••
Ohio State University
RECRUITING

Columbus, Ohio, 43210#, United States

Contact Email: •••••@•••••
The University of Alabama
RECRUITING

Birmingham, Alabama, 35294, United States

Contact Email: •••••@•••••
UZ Leuven
RECRUITING

Leuven, Belgium, 3000, Belgium

Contact Email: •••••@•••••
University Hospital Cologne Department of Internal Medicine I
RECRUITING

Cologne, 50937, Germany

Contact Email: •••••@•••••